MARKET

HALO

HALO

Halozyme Thrp
NASDAQ
47.91
-2.32
-4.62%
After Hours: 47.84 -0.07 -0.15% 18:53 05/14 EDT
OPEN
50.25
PREV CLOSE
50.23
HIGH
50.25
LOW
47.50
VOLUME
7.17M
TURNOVER
--
52 WEEK HIGH
70.51
52 WEEK LOW
42.01
MARKET CAP
5.90B
P/E (TTM)
12.71
1D
5D
1M
3M
1Y
5Y
1D
BUZZ-Halozyme falls after Morgan Stanley downgrades
Reuters · 5h ago
4 Stocks With Impressive Interest Coverage Ratio to Buy Now
NASDAQ · 7h ago
Halozyme Therapeutics Cut to Equal-Weight From Overweight by Morgan Stanley
Dow Jones · 8h ago
Halozyme Therapeutics Price Target Cut to $62.00/Share From $73.00 by Morgan Stanley
Dow Jones · 8h ago
Morgan Stanley Downgrades Halozyme Therapeutics to Equal-Weight, Lowers Price Target to $62
Benzinga · 8h ago
Halozyme downgraded at Morgan Stanley on price control risk
Seeking Alpha · 9h ago
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus
Barchart · 10h ago
TD Cowen Reaffirms Their Buy Rating on Halozyme (HALO)
TipRanks · 11h ago
More
About HALO
More
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Recently
Symbol
Price
%Change

Webull offers Halozyme Therapeutics, Inc. stock information, including NASDAQ: HALO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HALO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HALO stock methods without spending real money on the virtual paper trading platform.